Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation
about
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation
description
scientific article published on 16 November 2018
@en
name
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation
@en
type
label
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation
@en
prefLabel
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation
@en
P2093
P50
P1433
P1476
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation
@en
P2093
Björn Tackenberg
Brigitte Wildemann
Christian Eienbroeker
Christoph Aufenberg
De-Hyung Lee
Frederike Anne Straeten
Heinz Wiendl
Luisa Klotz
Marc Pawlitzki
Marinus Wieshuber
P304
P356
10.1007/S00415-018-9117-Z
P577
2018-11-16T00:00:00Z